O'Byrne Jason
EVP & Chief Financial Officer
O'Byrne Jason has filed 4 SEC Form 4 filings (6 transaction rows) across 1 company, with disclosures dating back to 2025. 4 of those filings fall inside the rolling window. Most recent filing: Mar 23, 2026.
On the most recent filing, O'Byrne Jason is listed as EVP & Chief Financial Officer at Vir Biotechnology, Inc. Inside the rolling window, O'Byrne Jason reported no open-market purchases and 3 open-market sales totaling $69K in VIR. The largest disclosed transaction in the window is a sale of 6,799 VIR shares on Nov 17, 2025, worth $38K.
Companies traded
Other insiders at VIR
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$69K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has O'Byrne Jason made?
O'Byrne Jason has filed 4 SEC Form 4 filings (6 transaction rows) across 1 company since 2025.
Which companies does O'Byrne Jason trade?
O'Byrne Jason has filed SEC Form 4 disclosures for 1 company, including VIR.
When was O'Byrne Jason's most recent SEC Form 4 filing?
O'Byrne Jason's most recent SEC Form 4 filing on Tracefour is dated Mar 23, 2026.
What is O'Byrne Jason's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, O'Byrne Jason is listed as EVP & Chief Financial Officer.
What is O'Byrne Jason's total buy and sell value in the current window?
Inside the rolling retention window, O'Byrne Jason bought $0 and sold $69K based on SEC Form 4 filings.
What was O'Byrne Jason's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 6,799 VIR shares on 2025-11-17, worth $38K, per SEC Form 4 filings.